A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
MOTS-c is a naturally occurring peptide encoded directly within your mitochondrial DNA — not your regular cell nucleus DNA — making it one of a small, unusual class of “mitochondrial-derived peptides.” It was discovered in 2015 by researcher Changhan Lee and colleagues, and it’s best described as a stress signal your mitochondria release under metabolic strain, one that naturally declines as you age. What makes it unusual is the direction it travels: the signal originates inside the mitochondrion and moves outward to communicate with the rest of the cell, the reverse of how most hormone signaling works.
MOTS-c works by disrupting a metabolic pathway to activate AMPK — your cells’ master energy sensor, the same one activated by exercise and fasting. In one striking animal study, just 7 days of MOTS-c completely restored insulin sensitivity in aged, insulin-resistant mice back to youthful levels — one of the more remarkable findings in this area of peptide research. Animal data also shows reductions in inflammatory markers. That said, this is still animal and cell-model research: while a related compound (CB4211) completed a Phase 1 human safety trial with a favorable profile, it was later discontinued before Phase 2, and MOTS-c itself has no completed published human trial as of this writing — though a new direct human trial began in 2026 and is currently underway.
“I have several patients that report increase in energy, mental clarity, and better quality of life with MOTS-c. Research isn’t where we want it on this one yet, however, the safety and benefits seem to outweigh the lack of information for a lot of people… This nutrient being a major part of standard energy production in the body makes it very safe to take.”
— Dr. Matt Chalmers, The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health
These pathways connect to NAD+ availability and mitochondrial biogenesis — both of which depend on niacin (vitamin B3, a direct NAD+ precursor), riboflavin, and magnesium (required for most ATP-dependent enzymatic steps). MOTS-c’s specific mechanism also runs through the folate cycle, so folate and B12 (ideally in their methylated forms) are rate-limiting cofactors — a deficiency here can blunt the mechanism regardless of dose.
MOTS-c is not FDA-approved for any indication and has two currently unresolved regulatory tracks. On the compounding side, it was removed from the FDA’s 503A Category 2 list on April 15, 2026 (a procedural step, not an approval), with a Pharmacy Compounding Advisory Committee review held July 23–24, 2026 alongside BPC-157, TB-500, and KPV; FDA staff briefing materials proposed against inclusion on the list that would make compounding lawful. Separately, MOTS-c is on the World Anti-Doping Agency’s Prohibited List (banned at all times, with no therapeutic use exemption available), so athletes subject to testing should be aware of this regardless of clinical rationale. This page is educational and not an offer to treat any condition.
Research has examined MOTS-c’s relationship to AMPK activation and glucose metabolism in laboratory and animal models, with striking results in aged, insulin-resistant mice. It is not FDA-approved for any indication, and this describes research findings rather than a demonstrated human outcome — a direct human trial is in progress but not yet complete.
It’s one of a small number of identified peptides encoded within mitochondrial DNA rather than nuclear DNA, a distinguishing feature that’s driven separate scientific interest in its signaling role.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
